Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07814066) titled 'A Multicenter, Open-label, Phase II Umbrella Study to Evaluate the Efficacy and Safety of the Investigational Product in Participants With Advanced or Metastatic Pancreatic Cancer' on Sept. 2.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Condition:
Pancreatic Cancer
Intervention:
Drug: SKB571
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: October 31, 2026
Target Sample Size: 30
To know more, vis...